NCT01621763

Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fed Conditions

An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover Oral Bioequivalence Study of Clopidogrel 300 mg Tablets of Dr. Reddy's India and Plavix® 300 mg Tablets Under Fed Conditions

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 68 (actual)
• Sponsor: Dr. Reddy's Laboratories Limited · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

To compare the bioavailability and characterize the pharmacokinetic profile of the Sponsor's formulation (Clopidogrel Bisulfate 300 mg Tablets) with respect to the reference formulation (Plavix® 300 mg tablets) in healthy, adult, human, male subjects under fed conditions and to assess the bioequivalence.

Detailed description

An open label, balanced, randomized, two treatment, two sequence, two period, single-dose, crossover oral bioequivalence study of Clopidogrel Bisulfate 300 mg Tablets of Dr. Reddy's Laboratories Ltd., India and Plavix® (Clopidogrel Bisulfate) 300 mg Tablets of Bristol-Myers Squibb/Sanofi pharmaceuticals partnership Bridgewater, NJ 0880750086441, USA, in healthy, adult, human male subjects under fed conditions.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Clopidogrel	Clopidogrel Tablets 300 mg

Timeline

• Start date: 2008-09-01
• Primary completion: 2008-09-01
• Completion: 2008-09-01
• First posted: 2012-06-18
• Last updated: 2012-06-25

Locations

1 site across 1 country: India